http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108864061-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4894735bbc0f3b539ecdd139b9e139f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
| filingDate | 2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37a319bb8d1d6ed21108211ebd1d50c5 |
| publicationDate | 2018-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108864061-A |
| titleOfInvention | A selective PI3K inhibitor for the treatment of tumors |
| abstract | The invention discloses a compound as shown in formula I or its pharmaceutically acceptable salt, ester, stereoisomer and solvate, Wherein, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from H or CN. Carry out PI3K kinase activity test by ADP-Glo technology and draw that the compound of the present invention is the selective inhibitor of PI3Kα, adopt CelltiterGlo assay method to carry out the in vitro inhibitory activity experiment of BT474 and draw that the compound of the present invention has in vitro inhibitory activity, illustrate that the compound of the present invention can be used as Cancer treatment drugs are more in-depth research. |
| priorityDate | 2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.